Scythian Biosciences – Developing CBD-Based Treatment for Traumatic Brain Injuries

An estimated 1.7 million people sustain a traumatic brain injury (TBI) annually in the US, according to data from the Centers for Disease Control (CDC), and the world of contact sports continues to be a major contributor to these alarming stats.

The NFL reported a 58% jump in concussions during the 2015 season, its highest in four years of reporting.

Youth sports saw a 500% surge in concussion diagnoses between 2010 and 2014, with the highest prevalence of injuries reported in September and October each year, peak time for youth football.

In total, TBI’s annual cost is estimated at $76.5 billion in the US.

Growing prevalence and significant costs are driving researchers to seek solutions, yet treatment options remain elusive. Calgary-based Scythian Biosciences (TSXV: SCYB) is working to change that.  

Innovative Clinical Research

SCYB is developing a solution for the prevention and treatment of TBI using its proprietary Cannabinoid ("CBD") combination therapy.

CBD is the naturally occurring, non-psychoactive chemical in marijuana.

Researchers have identified the Cannabinoid CB-2 receptor as a target for inflammation-dependent neurodegeneration. CBD acts as a CB-2 agonist and presents a broad range of anti-inflammatory and immune inhibitory effects.

If clinical trials prove successful, SCYB could develop the first pharmacologically-based drug regimen that successfully treats head trauma and concussions.

World-Class Collaborations & Endorsements

With tremendous potential from its innovate approach, SCYB recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its CBD-based drug regimen.

The five-year study at the University of Miami’s Miller School of Medicine expands on the science behind two pending patents written by SCYB Chief Operating Officer David Schrader.

To fund development, SCYB has raised approximately C$16 million (approx. $12 million US) year-to-date.

Pre-clinical work is already underway, and Phase 1 trials are expected to begin in 2018.

SCYB is well on its way to developing the first accepted drug regimen for concussive treatment, a mission endorsed by the NFL Alumni Association and the World Boxing Association.

High Valuations for Cannabis-Related Pharma Companies

Relatively new to the capital markets, SCYB is still under the radar of most investors, trading for a mere fraction of the valuation of more well-known cannabis-related pharma stocks.

Zynerba Pharmaceuticals (NASDAQ: ZYNE), a clinical-stage pharma developing and commercializing proprietary synthetic cannabinoid therapeutics for epilepsy and fibromyalgia, commands a $225 million valuation.

GW Pharmaceuticals (NASDAQ: GWPH) is also working on development of a host of cannabis-derived treatments and trades for a whopping $2.6 billion valuation.

With multiple upcoming milestones, we anticipate interest in SCYB to pick up significantly. Even reaching a fraction of these valuations will result in exponential gains from current levels. Early investors buying in ahead of the bigger players will likely be well rewarded.




RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).

Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at and/or the Ontario Securities Commission (“OSC”) at

Scythian Biosciences (SCYB) is a client of RedChip Companies, Inc. SCYB agreed to pay RedChip Companies, Inc., a monthly cash fee for six (6) months of RedChip investor awareness services.

Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market